IRulya Therapeutics Inc. Common Stock
IRLA
39 hedge funds and large institutions have $145M invested in IRulya Therapeutics Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 11 increasing their positions, 10 reducing their positions, and 7 closing their positions.
40% more capital invested
Capital invested by funds: $104M → $145M (+$41.1M)
29% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 7
12.62% more ownership
Funds ownership: 9.17% → 21.79% (+13%)
10% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 10
5% more funds holding
Funds holding: 37 → 39 (+2)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$75.2M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$27.1M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$7.95M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.8M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
+$1.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alphabet Inc
Mountain View,
California
|
-$4.36M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$2.78M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.96M |
| 4 |
Morgan Stanley
New York
|
-$1.24M |
| 5 |
Goldman Sachs
New York
|
-$1.24M |
IRLA Hedge Fund Activity: Q3 2019 in Review
39 of the 4,575 institutional investors tracked by Wall St. Rank reported a position in IRulya Therapeutics Inc. Common Stock (IRLA) for Q3 2019, worth a combined $145M — up 40% from $104M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new IRLA positions and 7 closed out — a net gain of 2 holders — while 11 added to existing stakes and 10 trimmed.
The largest buyer was Capital Research Global Investors, opening a new position worth an estimated $75.2M. The largest seller was Alphabet Inc, cutting an estimated $4.36M.
- 39 institutional investors held IRulya Therapeutics Inc. Common Stock (IRLA) as of Q3 2019, up from 37 in Q2 2019.
- Funds reported $145M of IRulya Therapeutics Inc. Common Stock stock for Q3 2019, up 40% quarter-over-quarter.
- 9 funds opened new IRulya Therapeutics Inc. Common Stock positions in Q3 2019 and 7 closed out, a net change of +2 holders.
- The largest IRulya Therapeutics Inc. Common Stock buyer in Q3 2019 was Capital Research Global Investors, an estimated $75.2M added.
- The largest IRulya Therapeutics Inc. Common Stock seller in Q3 2019 was Alphabet Inc, an estimated $4.36M sold.
Based on aggregated 13F filings for Q3 2019.